ArticleInternational journal of impotence research2026
Hydroxyurea in the management of sickle cell disease-associated priapism: a scoping review.
Article in International journal of impotence research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prevalence and Predictors of Priapism Among Patients with Sickle Cell Disease: A Cross-Sectional Study.Medicina (Kaunas, Lithuania) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sickle cell disease (SCD) is an inherited hemolytic-hemoglobinopathy that affects the ability of erythrocytes to deliver oxygen in the body. Hydroxyurea is a pharmacologic agent that has been approved by the Food and Drug Administration (FDA) for the treatment of SCD crises since 1998. It has also been proposed as a therapy for recurrent ischemic priapism (RIP), recurrent prolonged or unwanted erections in the absence of sexual stimulation, which occurs commonly in SCD. The premise behind hydroxyurea's therapeutic effect is that it improves vascular function and hemoglobin metabolism. Its potential role in RIP is to normalize the nitric oxide (NO) signaling pathway, which is fundamental for the regulatory physiology of the erection response. Hydroxyurea has been investigated in diverse research studies, including a recent clinical trial, showing its potential benefit for treating RIP. In this article, we performed a scoping review of the effectiveness of hydroxyurea for the treatment of SCD-associated RIP.
Indexed as
Identifiers
40229587What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.